Companies
The Karawang facility is being developed by PT SK Plasma Core Indonesia, a joint venture between South Korea's SK Plasma and Indonesia's sovereign wealth fund INA, with an investment of US$150 million.
Potential therapy: People who recovered from COVID-19 donate convalescent plasma on Tuesday at the Indonesian Red Cross Jakarta’s blood donation center on Jl. Kramat Raya in Central Jakarta. The government on Monday launched the National Convalescent Plasma Drive to increase the recovery rate and reduce the fatality rate of COVID-19 patients. (JP/Seto Wardhana)
Health Minister Budi Gunadi Sadikin stated that the blood plasma processing facility in Karawang, West Java, which aims to reduce reliance on imported high-value biological medicines, could begin operations early next year."We [still] import these products, even though Indonesia has one of the world's largest blood resources due to its large population," Budi said on Wednesday in Jakarta, as quoted by Bisnis.
The plant is expected to produce up to 600,000 liters of plasma-derived products annually once fully operational, with pending regulatory approvals from the Food and Drug Monitoring Agency (BPOM).
